Lulizumab pegol

Drug Profile

Lulizumab pegol

Alternative Names: BMS-931699; Lulizumab

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Class Monoclonal antibodies; Polyethylene glycols
  • Mechanism of Action CD28 antigen modulators; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Sjogren's syndrome; Systemic lupus erythematosus

Most Recent Events

  • 03 Mar 2017 Bristol Meyers Squibb plans a phase I trial in Healthy volunteers in USA (NCT03058822)
  • 01 Oct 2016 Phase-II clinical trials in Sjogren's syndrome in USA (SC) (NCT02843659)
  • 21 Jul 2016 Bristol-Myers Squibb plans a phase II trial for Sjögren's syndrome in Australia, Chile, Hungary, Mexico, Poland, Puerto Rico, Russia and South Africa and USA (SC, Injection) (NCT02843659)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top